Geraldine Taylor and colleagues at The Pirbright Institute in the United Kingdom will develop a thermo-tolerant vaccine based on human adenovirus 5 (Ad5) against peste des petits ruminants (PPR), a highly contagious disease found in goats and sheep, that enables the distinction between infected and vaccinated animals (known as DIVA vaccines). Current live attenuated vaccines require cold storage, which is unavailable in many developing countries, and vaccinated animals cannot be differentiated from infected animals, complicating disease control efforts. Ad5-vectored vaccines are safe and effective in humans, inducing both antibody and cytotoxic T cell responses from the immune system. They will extend their preliminary work showing that Ad5-conjugated with surface glycoproteins from the PPR virus provides complete protection in goats by vaccinating local breeds of goats in Africa. They will also determine the minimum vaccine dose and the effect of adding a specific cytokine to enhance immunity.
More information about The One Health Concept: Bringing Together Human and Animal Health for New Solutions (Round 11)